Why this is a Good Time to Consider Investing in Noven Pharmaceuticals Inc. (NOVN)
This stock has begun to approach its 52-week low. It closed the trading day on February 22, 2008 at just $12.89 against a 12-month range of $26.85-12.50. The Operating Margin over the last four quarters has been negative. The US Food and Drug Administration (FDA) inspectors have censured the company for customer complaints related to a key brand. Regulators have also asked the company to wait until a competitive patent expires before launching a new presentation of a drug. It is tempting to move away from a stock with so many negatives. However, the consensus amongst analysts is to hold…